NCT06182696View on ClinicalTrials.gov

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

August 31, 2028

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
BIOLOGICAL

OriCAR-017

GPCRC5D-directed chimeric antigen receptor modified T cells

Trial Locations (5)

310003

RECRUITING

The First Affiliated Hospital College of Medicine Zhejiang University, Hangzhou

Unknown

NOT_YET_RECRUITING

Beijing GoBroad Hospital, Beijing

NOT_YET_RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

NOT_YET_RECRUITING

Tongji Hospital of Tongji University, Shanghai

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

OriCell Therapeutics Co., Ltd.

INDUSTRY

NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Biotech Hunter | Biotech Hunter